Abstracts 2022
- P001 Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on the IL23/IFNg axis
- P002 Glial cell line-Derived Neurotrophic Factor (GDNF) improves intestinal wound healing – A new target for IBD treatment?
- P003 Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease
- P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls.
- P005 The solute carrier LC22A4/Organic Cation Transporter (OCTN)-1 as a novel Inflammatory Bowel Disease determinant at the microbe-host interface.
- P006 MiR-192 is associated with stricturing phenotype in Crohn’s disease
- P007 ORMDL proteins shape homeostasis in the intestinal epithelium by regulating endoplasmic reticulum architecture and autophagy
- P008 Modulation of Wnt signaling via a Wnt mimetic improved epithelial healing without causing hyperplasia in a mouse colitis model
- P009 Integrin-b7+ cytotoxic MAIT cells are expanded in the colon of Ulcerative Colitis patients, correlate with disease severity and are targeted by vedolizumab therapy.
- P010 Adherent-Invasive Escherichia Coli strain O83:H1 induces inflammatory response in Crohn's disease
- P011 New insights into the pathogenic potential and signalling network of NKG2D+ CD4+ T-cells in Crohn’s Disease
- P012 The effect of Oncostatin M on human intestinal organoids
- P013 A single cell approach reveals immune cell dynamics in Inflammatory Bowel Disease (IBD) and highlights association of CD8 intraepithelial lymphocytes (IELs) with response to vedolizumab treatment
- P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission
- P015 Detection of endoscopic lesions from limited quality annotations in colonoscopy videos
- P016 Colonoids derived from UC patients retain higher transcriptional response to inflammatory triggers in-vitro, even after several passages
- P017 Transcriptional characterization of lymphocytic colitis and comparison to collagenous colitis
- P018 Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery
- P019 GS-1069518 is a potent and selective small molecule α4β7 inhibitor
- P020 Differential expression of miR-424-5p and miR-378c in stenotic and penetrating lessions of Crohn’s Disease associates with altered transcription of genes involved in vascular regulation
- P021 Vitamin D receptor-dependent protective effect of moderate hypoxia in a mouse colitis model Running title: Hypoxia prevents mouse colitis through VDR
- P022 Transcriptional biomarkers for vedolizumab therapy response in patients with moderate to severe Ulcerative Colitis.
- P023 Prevalence of malnutrition, risk of malnutrition and quality of life among patients with Inflammatory Bowel Disease.
- P024 CD40 and key CD40/CD154 pathway members are significantly upregulated in inflamed lesional IBD biopsies as shown by whole transcriptome AmpliSeq gene expression profiling and corresponding immunohistochemistry.
- P025 A review of the newly implemented Inflammatory Bowel Disease dietetic service
- P026 Inflammatory bowel disease does not preclude the presence of environmental enteropathy in Zambian adults
- P027 Effects of anti-TNF and anti-α4β7 drugs on circulating monocytes migratory capacity in inflammatory bowel disease
- P028 Inhibition of stromal glycolysis by targeting PFKFB3 decreases experimental colitis
- P029 Expression of miR-21 in mucosal biopsies give clues to anti-TNF treatment non-response in IBD children and adults
- P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas
- P031 Intestinal lymphoepithelial interactions in Crohn's disease: modeling alphaE-beta7 and NKG2D blockade
- P032 Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients
- P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment
- P034 DISRUPTive liquid biopsies in Inflammatory Bowel Disease (DISRUPT-IBD): Release of exosomal and molecular tissue signals by transabdominal ultrasound?
- P035 An examination of resting state functional connectivity in patients with active Crohn’s disease
- P036 Identification and functional analysis of stromal subsets in experimental IBD mouse models
- P037 MicroRNA-31 and microRNA-200 family reflect disease activity in Crohn’s disease: results from the BIOMIR study
- P038 Targeting the hepcidin-ferroportin axis with Nrf2 agonists to treat iron deficiency anaemia in Inflammatory Bowel Disease
- P039 The role of α4β7+CLA+ ‘dual tropic’ T cells in inflammatory bowel disease
- P040 Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON)
- P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies
- P042 Succinate promotes the conversion from white to beige adipose tissue in Crohn’s Disease
- P043 3-oxo-C12:2, a Quorum Sensing molecule from the gut, exerts anti-inflammatory effects through a bitter taste receptor
- P044 Enteric dopaminergic pathways in mouse and human intestinal inflammation
- P045 TIGIT expression differentiates regulatory from inflammatory Th1* gut-homing effector CD4+ T cells in inflammatory bowel disease patients
- P046 Effects of CB2 and TRPV1 stimulation on osteoclast overactivity induced by iron in pediatric inflammatory bowel disease
- P047 Effect of infliximab and vedolizumab on M1 and M2 macrophages derived from THP-1 cells.
- P048 Bridging the Gap Between Body and Soul: A Pilot Study Examining Inflammation and Depression / Anxiety in Inflammatory Bowel Disease Patients
- P049 The treatment effect of tonsil-derived mesenchymal stem cells (T-MSCs) via regulating programmed death-1/programmed death ligand-1 (PD-1/PD-L1) in ulcerative colitis
- P050 A comparison of the Gut Microbiota in Pregnant Women with and without Inflammatory Bowel Disease and Their Offspring in Hong Kong and United States
- P051 IFNγ-macrophages could mediate EMT in Crohn’s disease through the WNT pathway
- P052 Comparing T cell responses to food antigens in Inflammatory Bowel Disease patients and healthy donors
- P053 The intestinal complement system and its role in dysregulation of the intestinal B-cell compartment in Crohn’s Disease patients
- P054 LHFPL3-AS2 long non-coding (lncRNA) is reduced in mucosal biopsies of Crohn Disease, and its reduction in tissue culture disrupts epithelial polarity
- P055 Factors from human mesenteric adipose tissue control intestinal stem cell differentiation and proliferation in vitro
- P056 Local nanocarrier delivery of JAK1 siRNA for IBD treatment: an in vivo mouse model
- P057 Mucosal microbiota adapts to ATF6-induced alterations in host lipid metabolism with prognostic value in colorectal cancer
- P058 IL-36 signaling in Crohn’s disease – characterization of a patient with an IL36RA mutation
- P059 Diet controls segmented filamentous bacteria in driving Crohn’s disease-like inflammation in TNFdeltaARE mice
- P060 Unravelling the microbial-derived metabolic alterations in a T-bet-/- x RAG2-/- mouse colitis model
- P061 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course
- P062 31P MRS and MRI phenotyping of muscle metabolic quality in IBD fatigue
- P063 Expression of the coinhibitory receptor TIGIT on memory CD4+ T cells is induced by TCR ligation and retinoic acid co-stimulation and is elicited during microbial colonization of the intestine.
- P064 IMU-838, a Small Molecule DHODH Inhibitor in Phase 2 Clinical Trial for Ulcerative Colitis, Shows Potent Anti-inflammatory Activity in Cell-Culture-Based and In Vivo Systems
- P065 Determination of the cytokine pattern of human colon organoids derived from Inflammatory Bowel Disease patients
- P066 Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis
- P067 Human intestinal CD103+SIRPα+ conventional dendritic cells from patients with Crohn´s disease prime IL-17+ T-cells.
- P068 Discovery of IBD3540: A Novel Gut-Restricted Glutamate Carboxypeptidase II Inhibitor with Preclinical Anti-Colitis Activity
- P069 Design and delivery of anti-oxidant inorganic complexes mimicking the superoxide dismutase for inflammatory bowel diseases treatment.
- P070 Novel long-acting lipidated interleukin-22 normalises colonic inflammation in an acute DSS colitis model
- P071 Intestinal CD8+ T cell exhaustion is linked to disease activity in ulcerative colitis
- P072 Melanocortin MC3 and MC5 receptors expression is different according to colonic disease activity in Crohn’s Disease and Ulcerative Colitis biopsies: results from an immunohistochemical observational study.
- P073 Eosinophil depletion partially protects from colonic inflammation, but increases colonic collagen deposition in a DSS colitis model
- P074 SZN-1326 promotes colonic mucosal healing in an acute injury model of IBD by first accelerating epithelial regeneration and secondarily reducing inflammation
- P075 Neutrophils prevent rectal bleeding in Ulcerative Colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis
- P076 Patients with Inflammatory Bowel Disease show IgG immune responses towards disease-associated small intestinal bacteria
- P077 Different granulocyte subsets are involved in the pathogenesis in Crohn’s disease fistula
- P078 Vedolizumab Treatment of ex-vivo Human Ulcerative Colitis (UC) Explants Results in Altered Inflammatory Protein Secretion Profiles
- P079 The expression of some circulating micro RNAs and serum Vitamin D levels in IBD patients
- P080 ADS024 attenuates weight loss and decreases disease activity in DSS-induced colitis
- P081 Therapeutic Drug Monitoring of infliximab in Crohn’s Disease: Cut-off points during maintenance therapy.
- P082 The profibrogenic role of neutrophil extracellular traps in stenotic Crohn's disease: a new antifibrotic target?
- P083 An integrative analysis of DNA methylation and RNA-Seq data in human adipose-stem cells of Crohn’s Disease patients with different clinical activity
- P084 Secreted inflammatory protein profiles following treatment of ex-vivo human Ulcerative Colitis and Crohn’s Disease explants with licenced biologic therapies
- P085 Paneth cells translate dietary lipid exposure into gut inflammation
- P086 Mucosal microbiota modulate host intestinal immune signatures in Inflammatory Bowel Disease
- P087 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Impact of Ulcerative Colitis Symptoms on Daily Life
- P088 Metabolomic analysis reveals differences among UC and non-IBD human colonic resections: role of GPCRs
- P089 Long ncRNA Landscape in the Rectum of Treatment Naïve Early Onset Ulcerative Colitis Highlights Association with Severity and Early and Late Disease Outcome, with Potential Role in Epithelial Metabolic Functions
- P090 Unraveling the rewiring of cytokine signalling in Inflammatory Bowel Disease using a novel network biology approach
- P091 A single-cell RNAseq approach to understand and predict the efficacy of tofacitinib in Ulcerative Colitis
- P092 Humoral and T cell responses to COVID-19 vaccination in IBD
- P093 Probiotic strains Lactobacillus plantarum and Saccharomyces boulardii influence the fibrotic responses of human intestinal subepithelial myofibroblasts.
- P094 Transcriptomic and small RNA sequencing profile in ileal resections from complicated Crohn´s Disease patients
- P095 Anti-inflammatory effect of high acetate concentration on organoid-derived epithelial monolayer from patients with Ulcerative Colitis
- P096 Store-Operated Calcium Entry Controls Innate and Adaptive Immune Cell Function in Inflammatory Bowel Disease
- P098 Mucosal Microbiota Composition Predicts Infliximab Response in Inflammatory Bowel Diseases
- P099 Serum proteomic analysis reveals novel biomarkers associated with disease activity in pediatric patients with Crohn’s disease
- P100 Serum inflammatory protein profiling to corroborate selection of therapy naïve moderate-to-severe pediatric Crohn’s disease patients eligible for first-line infliximab treatment
- P101 Isosteviol Attenuates Dextran Sulfate Sodium-Induced Colitis by Maintaining the Intestinal Barrier Through PDK1/AKT/NF-κB Signaling
- P102 Changes in serum immune protein profiles following vedolizumab therapy in Inflammatory Bowel Disease.
- P103 Identifying CES-1 positive myeloid cells with mass cytometry as a potential therapeutic target for Crohn’s disease
- P104 Icariin Attenuates Intestinal Inflammation through Inhibition of the Nuclear Factor-ĸB signaling
- P105 Treatment of the lower gastrointestinal tract Klebsiella infections by recombinant bacteriocin KvarIa
- P106 Macrophages as a source of NOTCH Ligands in Crohn's disease: implications in fibrosis
- P107 IL10 secretion endows intestinal human iNKT cells with regulatory functions towards pathogenic T lymphocytes in Crohn's disease patients
- P108 Identifying Patient-Centered Future Research Priorities: A Report from the Patient Reported Outcomes after Pouch Surgery (PROPS) Delphi Consensus Study
- P109 Risk of cervical cancer in incident Ulcerative Colitis during the first 10 years after diagnosis: A nationwide population-based study
- P110 Risk Factors of Clinical Relapses in Pediatric Luminal Crohn’s Disease, a Retrospective Cohort Study
- P111 Gut barrier markers in Inflammatory Bowel Disease
- P112 The road to disease control: Combination of histologic and endoscopic remission predicts long-term disease outcome in ulcerative colitis
- P113 Defining the Safety of Early Ileostomy Closure After IPAA
- P114 SARS-CoV-2 infection in IBD: pandemic waves and predictors of severe or persistent COVID-19
- P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage
- P116 Screening for low BMI and unintentional weight loss alone is insufficient to identify patients at risk for malnutrition in an outpatient IBD population
- P117 point-of-care intestinal ultrasound for the detection of postoperative Crohn's disease endoscopic recurrence
- P118 Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
- P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series.
- P120 First year remission rates among patients with newly diagnosed Crohn’s disease: data from a real-world prospective inception cohort
- P121 Second-Line Biologic Therapy Persistence in a Multicentre Cohort of Inflammatory Bowel Disease Patients
- P122 Low Risk of new dysplastic lesions during inflammatory bowel disease surveillance with dye-cromoendoscopy: a multicenter population-based retrospective study
- P123 Characteristics of small bowel involvement and association with clinical outcome in patients with Crohn's disease
- P124 Views of patients with Inflammatory Bowel Disease on their care during COVID-19 pandemic
- P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
- P126 The predictive value of the modified Rutgeerts score at index endoscopy after primary ileocolic resection in patients with Crohn’s disease for the risk of re-resection and severe endoscopic inflammation after long-term follow-up
- P127 Type I collagen degradation fragments (C1M) and human neutrophil elastase-derived fragments of calprotectin (CPa9-HNE) reflect biochemical and endoscopic disease activity in patients with Inflammatory Bowel Disease
- P128 Accuracy of the combination of transabdominal and transperineal ultrasound for the evaluation of Ulcerative Colitis activity
- P129 Hepcidin and ferritin index can help to differentiate between different types of anaemia: an exploratory study
- P130 Comparison of the clinical course of Ulcerative Colitis according to the presence or absence of clinical symptoms at the time of diagnosis
- P131 Impact of Inflammatory Bowel Disease on patients’ caregivers: Results from a French cohort
- P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease.
- P133 Point-of-care measurement of infliximab and adalimumab trough levels by the fluorescence resonance energy transfer (FRET) assay
- P134 Are hepatic steatosis predictive scores still useful to predict metabolic associated fatty liver disease (MAFLD) in Crohn’s disease patients?
- P135 Usefulness of clinical and ultrasound indices to assess enthesis lesions in patients with inflammatory bowel diseases.
- P136 Risk of polyps and colorectal cancer in patients with microscopic colitis: case-control study with long-term follow-up
- P137 Lesions of Cytomegalovirus and Epstein Barr virus of the proximal gastrointestinal tract in patients with Inflammatory Bowel Disease after COVID-19.
- P138 Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe Ulcerative Colitis
- P139 Body composition and Crohn’s disease behavior: Is adiposity the main game changer?
- P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients
- P141 Factors Associated with Time to Clinical Remission in Pediatric Luminal Crohn’s disease: a Retrospective Cohort Study
- P142 Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study
- P143 Changes in the Clinical Phenotype and Behavior of Pediatric Luminal Crohn’s Disease at Diagnosis in the Last Decade
- P144 Changes of fecal metabolic and lipidomic features by anti-tumor necrosis factor treatment and prediction of clinical remission in patients with ulcerative colitis
- P145 Ultrasonographic parameters associated with mucosal healing 1 year after infliximab therapy in Crohn’s Disease: a multicentric and prospective study
- P146 Initial response to induction treatment more important than type of induction treatment for achieving sustained steroid free remission at 1 year in new-onset paediatric Crohn’s disease
- P147 Do IBD Patient Treatment Outcomes Expectations Differ by Ethnicity and Gender?
- P148 Subclinical inflammatory bowel disease precedes the diagnosis and leads to an increase on healthcare resources utilization: multicentric case-control study in the Basque Country
- P149 Prioritising colonoscopy by faecal immunochemical test result does not delay the diagnosis of inflammatory bowel disease
- P150 INCREASED RISK OF IBD FLARE AFTER SARS-CoV-2 INFECTION. WHO’S THE MORE GUILTY: VIRAL INFECTION OR THERAPY WITHDRAWAL?
- P151 Rationalizing colonoscopy utilization for Inflammatory bowel disease diagnosis: time to reset the Calprotectin threshold to >600?
- P152 Impact of disease location on burden of illness in patients with moderate-severe Crohn’s disease: A real-world survey in the United States, France, Germany, Italy, Spain, and United Kingdom (5EU)
- P153 The impact of seton use on clinical and patient-reported outcomes in Crohn’s disease perianal fistulas: findings from a systematic literature review
- P154 Evaluation of serum protein FingerPrint biomarkers of collagen, citrullinated vimentin and calprotectin in patients with inflammatory bowel disease
- P155 Incidence and significance of vitamin D deficiency at Inflammatory Bowel Disease inception in the COVID era
- P156 A multicentric study on the development and application of a deep learning algorithm for automatic detection of ulcers and erosions in the novel PillCam™ Crohn’s capsule
- P157 Biologic therapy and short disease duration correlate with no dysplasia when colectomy performed for ulcerative colitis
- P158 Disease and non-disease-related risk factors for inadequate bowel preparation in patients with inflammatory bowel disease: should the strategy be different?
- P159 Faecal S100A12 as a non-invasive marker of inflammatory activity in Inflammatory Bowel Disease
- P160 Pan-enteric mucosal inflammation in CD patients treated with vedolizumab – interim results of a prospective observational study using a panenteric capsule (PiilCam CD)
- P161 Implementation of Outcome Measurement – Case Finnish IBD register
- P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression
- P163 Abdominal X-ray: an invaluable tool in Acute Severe Ulcerative Colitis
- P164 Assessment of awareness and compliance with the recommendations of primary and secondary prevention of cancer in patients with Inflammatory Bowel Disease
- P165 Characterization and risk of sarcopenia in patients with Ulcerative Colitis, compared with older and younger adults. Cross-sectional study.
- P166 Predictive markers of Crohn’s disease in small bowel capsule endoscopy
- P167 Functional outcomes of transanal versus transabdominal proctectomy with ileal pouch-anal anastomosis in Ulcerative Colitis. A comparative study.
- P168 Matrix Gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in Crohn’s Disease
- P169 Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources
- P170 Point-of-care ultrasound accurately quantifies skeletal muscle index in patients with Inflammatory Bowel Disease
- P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE)
- P172 Examining dysplasia surveillance in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis - a real world experience.
- P173 Endoscopic findings in the upper gastrointestinal tract in Crohn’s Disease – highly specific and closely related to Helicobacter pylori negative gastritis.
- P174 Clostridium innocuum Infection in Inpatients with Inflammatory Bowel Disease
- P175 Low relapse rates after biologic therapy discontinuation in a large real life cohort of IBD patients with initial severe disease: do biologics alter the natural history of disease?
- P176 The effect of induction therapy with infliximab or vedolizumab on hepcidin and iron status in patients with Inflammatory Bowel Disease
- P177 Validation of UC Intestinal Ultrasound (UC-IUS) Index for children with Ulcerative Colitis
- P178 Fecal incontinence and rectal anal function in Crohn’s Diseases patients
- P179 Distinct ultrasound characteristics of the appendix in patients with ulcerative colitis: a prospective, cross-sectional cohort study
- P180 The prevalence and clinical course of atypical distribution of inflammation in newly diagnosed ulcerative colitis
- P181 IBD patients with early clinical and sonographic improvements achieve better long-term outcomes than patients with clinical improvements alone – one-year interim results of the TRUST BEYOND study
- P182 Twisted Pouch Syndrome: A Rare, Difficult to Diagnose Mechanical Complication of Ileal Pouch-Anal Anastomosis Amenable to Redo Pouch Salvage Surgery
- P183 A systematic review on outcome measures of long-term efficacy in clinical trials concerning Crohn’s disease patients
- P184 Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study
- P185 The role of neutrophil-lymphocyte ratio, neutrophil-monocyte ratio, and lymphocyte-monocyte ratio in estimating disease activity in patients with ulcerative colitis.
- P186 Can transabdominal bowel ultrasound accurately detect both small and large bowel Crohn Disease in pediatric patients when compared to MRE?
- P187 Major Depression in patients with Ulcerative Colitis and its relationship with clinical activity.
- P188 Role of gastrointestinal ultrasound in severe Ulcerative Colitis: a real-life observational study from a tertiary center in Spain.
- P189 Perceptions of Cannabis use in women with Inflammatory Bowel Disease of reproductive age: A cross-sectional study
- P190 Implementation of IBD symptom diary – Case Finnish IBD register
- P191 Development and validation of a 13-item short version of the IBD self-efficacy scale
- P192 First event of acute intestinal inflammation and the risk of progression to Inflammatory bowel disease: a retrospective analysis
- P193 Correlation of the IBD Disk scores with diagnosis of IBD, Faecal calprotectin and Endoscopic scores in patients presenting to a rapid access IBD inception clinic.
- P194 A modified Rutgeerts score of i2a after ileocolic resection for Crohn’s Disease: endoscopic recurrence or anastomotic healing?
- P196 Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure
- P197 Anogenital Crohn’s disease and granulomatosis: A systematic review of epidemiology, clinical manifestations, and treatment
- P198 An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease
- P199 Ileal pouch-anal anastomosis in women of childbearing age affected by ulcerative colitis: a single-centre study on the risk factors for infertility and outcomes of pregnancy over 17 years.
- P200 The diagnostic yield of pan-enteric capsule endoscopy in inflammatory bowel disease: A systematic review and meta-analysis
- P201 Crohn’s Disease of the terminal ileum associated with ileo-sigmoid fistula: risk factors for ileostomy formation and postoperative complications during the years of biologics
- P202 Performance characteristics of serum FGF19 measurement compared with the Se-HCAT retention test in the diagnosis of bile acid diarrhoea in Crohn’s Disease
- P203 The performance of the Rutgeerts’ score, SES-CD, and MM-SES-CD for prediction of post-operative clinical recurrence in Crohn’s disease
- P204 Endotrophin (PRO-C6) is associated with MRE confirmed intestinal strictures and Protein FingerPrint biomarkers of collagen degradation is associated with ulcerations in paediatric Crohn’s disease patients – results from the ImageKids study
- P205 Eliakim and CECDAIic scores are useful pan-intestinal tools for CD diagnosis and activity monitoring
- P206 Comparison of dye-spraying chromoendoscopy and virtual chromoendoscopy for colonic dysplasia detection in longstanding Inflammatory Bowel Disease
- P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents
- P208 Enthesopathies in patients with inflammatory bowel diseases.
- P209 Disproportionate low albumin and high neutrophil-to-lymphocyte ratio in small bowel adenocarcinoma in long-term Crohn's disease patients
- P210 Assessment of disease specific knowledge and quality of life among patients with Inflammatory Bowel Disease
- P211 Vaccination against Sars-Cov-2 in IBD patients: experience from a single tertiary referral centre
- P212 The DUBLIN Score is a Useful Tool for Predicting Disease Course in Patients with Ulcerative Colitis
- P213 Risk factors associated with NAFLD and liver fibrosis in patients with Inflammatory Bowel Disease: a prospective cohort study
- P214 Plasma fatty acid binding protein 2, interleukin-10 and lipopolysaccharides as biomarkers for microscopic colitis
- P215 Correlation between small bowel capsule endoscopy and biomarkers in postoperative recurrence in Crohn’s Disease
- P216 Effect of the Crohn’s disease exclusion diet (CDED) on the fecal calprotectin level in children with active Crohn’s disease.
- P217 Prevalence of COVID-19 in IBD patients treated with infliximab and vedolizumab in Croatian tertiary center – clinical observation of a case series
- P218 Accuracy of Ultrasonography in Assessing Disease Activity in Pediatric Ulcerative Colitis: Preliminary Results of a two-center study
- P219 Impact of COVID-19 pandemic in patients with a first consultation for suspected inflammatory bowel disease.
- P220 CROHN'S DISEASE (CD): The predictive value of Montreal clinical patterns, and biological treatment in a Latin American IBD reference center.
- P221 Association between Irritable Bowel Syndrome-type symptoms and Ulcerative Colitis: is it real?
- P222 Raman Spectroscopy in the diagnosis of pIBD: experimental study
- P223 Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patient with intestinal Behçet’s disease as a marker of disease activity and prognosis
- P224 Deconstructing distress: Stakeholder engagement for evidence-based, patient-centered interventions for the management of IBD-associated psychological distress
- P225 David against Goliath: direct comparison of hand-held bowel sonography and magnetic resonance enterography for diagnosis of Crohn's disease
- P226 Nuclear magnetic resonance spectroscopy measure of protein glycosylation is a biomarker of activity and metabolic complications in Inflammatory Bowel Disease.
- P227 High prevalence of mental health illness in IBD patients with high caregiver burden in the developing world: An analysis of risk factors from the IBD Emerging Nations Consortium (IBD-ENC)
- P228 Appendiceal Orifice Inflammation Is Associated with Lower Rate of Complete Endoscopic Remission in Patients with Ulcerative Colitis
- P229 Capsule endoscopy is useful in the diagnosis and monitoring of postoperative recurrence in Crohn’s disease. Analysis from an 11-year cohort.
- P230 Ultrasonography-based and Magnetic Resonance-based Lémann Index: two sides of the same coin
- P231 Emergency Colectomy for IBD Is Not Associated with Increased Risk of Postoperative Infection, Reoperation or Readmission
- P232 Depression and fatigue in active IBD from a microbiome perspective - a bayesian approach to faecal metagenomics
- P233 Efficacy and safety of oral sulfate tablet for the bowel preparation in patients with inflammatory bowel disease: multicenter randomized controlled study
- P234 Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study
- P235 The natural history of COVID-19 in vaccinated Inflammatory Bowel Disease patients
- P236 Interobserver reliability of the Nancy index for ulcerative colitis: An assessment of the practicability and ease of use in a single-centre real-world setting.
- P237 Proteomic analyses do not reveal subclinical inflammation in fatigued patients with quiescent Inflammatory Bowel Disease
- P238 Symptom burden and indolent disease in newly diagnosed patients with ulcerative colitis and Crohn’s disease - a Copenhagen IBD Inception Cohort Study
- P239 Ulcerative Colitis Index of Severity is a better predictor of histologic activity than Mayo endoscopic subscore, an Asian cohort study in ulcerative colitis.
- P240 Influence of Covid-19 infection in patients with inflamatory bowel disease with biological and no biological therapy
- P241 Advantages of a fully automated chemiluminescent method for therapeutic drug monitoring (TDM) of anti-TNFα in patients with Inflammatory Bowel Diseases
- P242 Latent Tuberculosis: frequency of occurrence and effect on clinical, laboratory, endoscopic and morphological activity of the course Inflammatory Bowel Diseases
- P243 Relationship between intestinal ultrasound, fecal calprotectin and Harvey-Bradshaw Index in the assessment of infllamatory activity in Cronh´s Disease
- P244 COVID-19 vaccine does not increase the likelihood of disease exacerbation in IBD: results from a population-based study
- P245 Dynemics of the Immune-transcriptome and Microbiome in Paediatric Inflammatory Bowel Disease
- P246 Persistent burden of disease in patients with Crohn’s disease treated with biologic therapy: results from a real-world survey in the United States (US), France, Germany, Italy, Spain, and United Kingdom (5EU)
- P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts
- P248 Lifestyle changes after Inflamatory Bowel Disease diagnosis.
- P249 Serum calprotectin is useful to confirm Inflammatory Bowel Disease activity but is not effective to predict relapse.
- P250 Clinical validation of a point of care test for fecal calprotectin in distinguishing irritable bowel syndrome from Inflammatory Bowel Disease
- P251 Endoscopic and pathologic findings of the esophago-gastroduodenal involvement of Crohn’s disease in Korea: a prospective cohort study
- P252 Low adherence is associated with worse disease course in Ulcerative Colitis: a retrospective study from a single referral center.
- P253 Are we doing enough to prevent colectomy in Inflammatory Bowel Disease (IBD) patients? A 5-year review of colectomy rates in Shropshire and Mid-Wales UK (2015-2019).
- P254 Crohn’s disease of the pouch: an overdiagnosed condition?
- P255 Mirikizumab modulates genes associated with the symptom of bowel urgency
- P256 The practical use of an eHealth platform for inflammatory bowel disease patients: the validation of the IBD Tool web-based tele-monitoring system
- P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn’s disease
- P258 Impact of inflammatory bowel diseases on the phenotype and severity of primary sclerosing cholangitis - a systematic review with meta-analysis
- P259 Metabolic associated Liver Disease and sex as key factors of cardiovascular risk in Inflammatory Bowel Disease
- P260 Autoimmune pancreatitis in patients with Inflammatory Bowel Disease: results from a multicentre ECCO CONFER cases series
- P261 Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients – real world global study analyses
- P262 Decreased infliximab trough levels (TLI) is a moderate predictor of loss of response to IFX in IBD patients.
- P263 Very early onset Inflammatory Bowel Diseases: Review of the Genoa-Messina joint clinical experience. Clinical history: Part I.
- P264 Prevalence and predictors of stoma formation and restoration of intestinal continuity in patients with Crohn’s disease in a tertiary referral hospital: A retrospective explorative study
- P265 Open approach for ileocolic resection in Crohn’s disease in the era of minimally invasive surgery: indications and perioperative outcomes in a referral centre.
- P266 Elderly-onset Inflammatory Bowel Disease: a retrospective single-center study with current follow-up
- P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis
- P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave
- P269 Spaciotemporal machine learning analysis of complete small bowel capsule endoscopy videos for prediction of outcomes in Crohn's disease
- P270 Ultrasonography interobserver agreement in Crohn Disease between experienced and non expert operators
- P271 Fecal calprotectin at diagnosis is associated with oral steroid use first year of Inflammatory Bowel Disease.
- P272 Psychological burden in newly diagnosed IBD patients: Differences between Crohn's Disease and Ulcerative Colitis in early IBD
- P273 Inflammatory Bowel Disease and COVID-19 vaccine
- P274 Bioelectrical impedance analysis identifies low skeletal muscle index in patients with Inflammatory Bowel Disease
- P275 New non-invasive biomarkers of intestinal inflammation in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin – pilot study.
- P276 Prevalence, clinicopathological, and biological characteristics of serrated polyps in patients with ulcerative colitis
- P277 Assessment of fatigue as a patient-reported outcome: Correlation with baseline disease activity and therapy response in Inflammatory Bowel Disease
- P278 Pan-enteric capsule to assess treatment effects of vedolizumab in IBD patients: A 1 year proof of concept study
- P279 Prevalence of iron deficiency in inflammatory bowel disease
- P280 Prognosis of patients with Crohns Disease in transmural remission with gastrointestinal ultrasound
- P281 TELEIBD: A telematic fast-track pathway for patients with high suspicion of Inflammatory Bowel Disease in primary care.
- P282 Influence of phenotype at diagnosis and of other potential prognostic factors on the prognosis of Crohn’s Disease in Chinese population
- P283 Infliximab re-challenge: could it be an option in refractory IBD patients?
- P284 Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn’s disease: a prospective study based on clinical risk stratification
- P285 Longitudinal single cell transcription profiling of peripheral blood disentangles shared and biologic-specific patterns of early remission in active IBD patients
- P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
- P287 The knowledge and skills needed to perform intestinal ultrasound – An international Delphi consensus survey
- P288 Recurrence rates of advanced neoplasia after endoscopic or surgical resection in Inflammatory Bowel Disease patients: a retrospective cohort study
- P289 Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project.
- P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
- P291 Effect of the preconception steroid-free remission period on disease activity during pregnancy and birth outcomes in women with Ulcerative Colitis: a retrospective cohort study
- P292 Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis.
- P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe
- P294 On the way to disease control: Fatigue as part of a novel composite endpoint in an analysis of a prospective open label observation trial
- P295 Proctitis during Crohn's disease, would it be a factor in the sustainability of anoperineal fistulas ?
- P296 vedolizumab Does Not Increase Risk of Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease Using vedolizumab: a Retrospective Cohort Study
- P297 Treatment of patients with complex perianal Crohn's disease with darvadstrocel: a single-institution real life experience.
- P298 Pregnancy in Crohn's and Colitis - Observations, Levels and Outcomes Extension (PICCOLO-X) Study: Biological therapy reduces faecal calprotectin and the need for corticosteroids in pregnant women with Inflammatory Bowel Disease
- P299 Prediction model for steroid-free clinical remission with vedolizumab at week 22 in patients with Ulcerative Colitis: Machine learning using clinical data at baseline
- P300 Very early onset Inflammatory Bowel Diseases: Review of the Genoa-Messina joint clinical experience. Therapeutic approach: Part II
- P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease.
- P302 Malignancy surveillance in patients with primary sclerosing cholangitis and Inflammatory Bowel Disease – keeping up with international guidelines? A Norwegian cohort study
- P303 Biologic Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease: Are we aiming high?
- P304 Intensified versus conventional infliximab induction in acute severe steroid-refractory Ulcerative Colitis
- P305 Low ALT is more Common in Patients with IBD than Healthy Controls and is Associated with Active Disease
- P306 Efficacy and tolerance of sodium picosulfate preparation in bowel Magnetic Resonance Imaging in Crohn’s disease
- P307 The effect of COVID-19 infection and vaccination in patients with Inflammatory Bowel Disease and Irritable Bowel Syndrome.
- P308 Quadruple oral antibiotic treatment in refractory Paediatric Inflammatory Bowel Disease – incidence and analysis of responders from a 10 year cohort.
- P309 Withdrawal of thiopurines in Inflammatory Bowel Disease patients in stable remission: a prospective, multicentre cohort study
- P310 Atopic dermatitis is associated with the clinical course of Inflammatory Bowel Disease
- P311 Depression and anxiety are associated with poor clinical outcomes in Inflammatory Bowel Disease : A Nationwide Population-Based Study in South Korea
- P312 Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trial
- P313 Within 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses
- P314 Elderly onset is associated with low efficacy of anti-TNF treatment in Bio-naïve IBD patients: A multicenter cohort study by the Osaka Gut Forum
- P315 High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study
- P316 Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North
- P317 Ustekinumab Trough Concentrations Associated with Biochemical Outcomes in Patients with Crohn’s Disease
- P318 Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis
- P319 Incorporating HLADQA1*05 in pre-biologic screening in IBD patients initiating biologic therapies
- P320 6-Thioguanine nucleotide levels are associated with trough levels of infliximab and adalimumab in Inflammatory Bowel Disease patients on combination therapy: A retrospective multicentre study
- P321 Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm study
- P322 Effectiveness of Tumor Necrosis Factor-alpha inhibitors and Thiopurines combination therapy according to 6-thioguanine nucleotides plasma levels: A Systematic Review.
- P323 The Crohn's Disease Exclusion Diet (CDED) for pouch inflammation: an interventional pilot study
- P324 Tacrolimus for induction of remission in refractory ulcerative colitis: a Cochrane systematic review
- P325 Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's disease
- P326 The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s disease
- P327 Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring
- P328 In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease
- P329 Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients
- P330 Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccination
- P331 Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
- P331 Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
- P332 Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).
- P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
- P334 Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.
- P335 Utility of Intestinal Ultrasound in Monitoring Disease Activity in Ulcerative Colitis Patients Treated with Biologics
- P336 Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot study
- P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum
- P338 Early proactive drug monitoring strategy of infliximab as monotherapy for inflammatory bowel disease in paediatric patients is associated with good sustained clinical remission
- P339 Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with Inflammatory Bowel Disease
- P340 Risankizumab in Crohn's disease: Real World Experience from a Pre-Approval Access Program
- P341 Pharmacokinetics and exposure-response analyses of upadacitinib in patients with moderate to severe ulcerative colitis – Analyses of induction and maintenance clinical trials
- P342 Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium
- P343 Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAID
- P344 What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis
- P345 The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn’s Disease
- P346 Chronic pouch failure rates after close rectal dissection and total mesorectal excision in ileal pouch-anal anastomosis.
- P347 Sarcopenia is a poor prognostic factor for endoscopic outcomes in patients with Crohn’s disease
- P348 Top down versus step-up strategies to prevent postoperative recurrence in Crohn’s disease
- P349 Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU).
- P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.
- P351 Allogenic adipose-derived mesenchymal stem cells (darvadstrocel) in Japanese patients with complex perianal fistulas in Crohn’s disease
- P352 Ustekinumab is associated with superior treatment persistence compared to vedolizumab in Crohn’s disease patients who failed to anti-TNF therapy: results from a Hungarian cohort study
- P353 Agreement between patients, senior and junior physicians on disease activity and burden scoring in inflammatory bowel disease, using a tele-monitoring platform
- P354 Immunological response to vaccination against SARS-COV-2 infection in Inflammatory Bowel Disease patients under immunosuppressive therapy: should we prioritize an additional booster injection?
- P355 Exceeding treatment expectations in Crohn's disease: transmural healing and a new definition of deep remission
- P356 Czech experience with treatment of Crohn´s disease perianal fistulas by allogenic mesenchymal stem cell
- P357 Monitoring of Thiopurines and Methotrexate in Inflammatory Bowel Disease: Are we Monitoring Too Frequently? A Cross Sectional Study.
- P358 Keeping it simple: How a streamlined referrals process reduces the time taken to initiate biologic therapy
- P359 Radiomics could predict surgery at 10 years in Crohn’s disease
- P360 The correlation between ophthalmological posterior segment findings and disease severity in patients with inflammatory bowel disease
- P361 PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis
- P362 Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.
- P363 Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?
- P364 Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA®) in monotherapy and in combination with azathioprine
- P365 Weight gain after initiation of adalimumab in patients with Crohn’s disease
- P366 Exclusive enteral nutrition drives protective microbiome modulation in paediatric Crohn's Disease
- P367 quality of life in patients with Inflammatory Bowel Disease
- P368 Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center
- P369 Dual Biologic in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series
- P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase 3 study U ACHIEVE maintenance
- P372 Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s disease
- P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety
- P374 Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulas
- P375 Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patients
- P376 Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
- P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
- P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open
- P379 Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?
- P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease
- P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis
- P382 Novel Image Enhanced Endoscopy (IEE) technologies for surveillance of colonic Inflammatory Bowel Disease: A pilot study evaluating Texture and Colour Enhancement Imaging (TXI) and Linked Colour Imaging (LCI) as compared with chromoendoscopy.
- P383 Ustekinumab as an opportunity for refractory Ulcerative Colitis patients.
- P384 Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
- P385 Tailoring induction treatment for children with Crohn’s disease.
- P386 Predictive models for assessing the response to ustekinumab in Crohn’s disease patients
- P387 Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) Program
- P388 Asking teenagers and young adults with IBD; “what matters to you?”. A qualitative survey during the COVID-19 pandemic
- P389 Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom
- P390 Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn´s disease: multicentric experience in the Basque Country and Navarre
- P391 Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacy
- P392 To study the prevalence of depression and anxiety in patients of Inflammatory Bowel Disease (IBD) and the efficacy of psychopharmacotherapy in these patients: A pilot study
- P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis.
- P394 A prospective analysis of body composition in patients with Inflammatory Bowel Disease and changes during biologic therapy
- P395 Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab
- P396 COVID-19 pandemic-related endoscopy delays did not translate to deleterious outcomes for patients with Inflammatory Bowel Disease: A retrospective cohort study
- P397 Can upskilling pharmacy technicians support a robust and cost-effective Inflammatory Bowel Disease patient review process? A single-centre prospective study.
- P398 Long term efficacy and safety of ABP 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
- P399 C-Reactive Protein Values After Surgery for Inflammatory Bowel Disease: Is It Still A Good Marker For Intra-Abdominal Complication? A Retrospective Cohort Study of 347 procedures.
- P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
- P401 Tofacitinib tissue exposure correlates with endoscopic outcome
- P402 Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program
- P403 The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.
- P404 Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials
- P405 Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank Project
- P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates
- P407 A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: An interim analysis
- P408 Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis
- P409 FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial
- P410 safety of biological drugs for inflammatory bowel disease in elderly patients
- P411 Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
- P412 Drug persistence and endoscopic, histologic and biochemical remission rates among patients following ileal pouch-anal anastomosis treated with biologic therapy: Results from a prospective patient cohort.
- P413 Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b2 vaccines in the immunosuppressed (RESCUE)
- P414 Stoma in patiens with IBD: friend or foe? -\tEffect of stoma on course of disease, psychological well-being and working capacity
- P415 Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial
- P416 Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease
- P417 Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients
- P418 Development and validation of a digital health platform (IBD NutriCare) for telenutrition in patients with Inflammatory bowel disease
- P419 Long-term outcome of ulcerative colitis in pediatric patients who achieved mucosal and histological healing: a real-life referral center experience
- P420 Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure
- P421 Correlation of bowel activity parameters in intestinal ultrasound to drug retention and trough drug levels in Crohn's disease
- P422 How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
- P423 Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.
- P424 Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations
- P425 Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy
- P426 Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis
- P427 Exploring phenotype and treatment of inflammatory bowel disease in the elderly
- P428 A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysis
- P429 Mesalazine has no place in the treatment of Crohn's disease. Really?
- P430 Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study
- P431 Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial
- P432 Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase 3 clinical trial
- P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.
- P434 The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
- P435 High rate of vitamin deficiencies in patients after total proctocolectomy and pouch surgery- results from a prospective cohort
- P436 Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
- P437 Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.
- P438 The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.
- P439 Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.
- P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.
- P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.
- P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis
- P443 Trough concentration response in infliximab and adalimumab treated children with IBD following treatment adjustment: A pharmacokinetic model.
- P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort
- P445 Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from Hungary
- P446 Long-term Clinical Effectiveness And Stoma Outcome Of Fecal Diversion In Refractory Crohn’s Proctitis
- P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease
- P448 Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
- P449 Autologous fat graft injection for the treatment of perianal fistulas in Crohn’s disease: A systematic review and single-arm meta-analysis
- P450 Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease
- P451 Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective study
- P452 Tofacitinib Effectiveness and Safety as Therapy for Ulcerative Colitis
- P453 Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease
- P454 Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease
- P455 Aminosalicylates in Ulcerative Colitis: old but gold?
- P456 Risk of malignant tumors in patients with autoimmune diseases on ustekinumab therapy: a systematic review and meta-analysis
- P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis
- P458 Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn's disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHAN
- P459 High inadequate surveillance rates in colitis-associated advanced neoplasia: a multicenter retrospective cohort study
- P460 A Real-World Picture of Adverse Drug Reactions in Inflammatory Bowel Disease
- P461 COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysis
- P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response
- P463 Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity marker
- P464 Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?
- P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
- P466 Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
- P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice
- P468 Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study
- P469 Infliximab for induction of medically-induced remission in Crohn's disease: a Cochrane systematic review
- P470 Real-world characteristics and complications of patients with Ulcerative Colitis receiving conventional therapy in the public healthcare system in Brazil
- P471 Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients
- P472 Changes in colectomy for Ulcerative Colitis during the last two decades: an in-depth retrospective analysis
- P473 Real world experience with the Crohn's Disease Exclusion Diet (CDED) in a tertiary IBD clinic
- P474 Prevalence of fecal incontinence and clinical characteristics of IBD patients in remission and treated with biologics – experience from a tertiary referral center
- P475 Profiling the use of Complementary Alternative Medicines among IBD patients
- P476 Disease recurrence patterns in patients undergoing bowel resections for Crohn’s disease.
- P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open
- P478 The role of proactive measurement of adalimumab trough levels and antibodies to adalimumab in Greek patients with Inflammatory Bowel Disease
- P479 Trends in medication use and treatment patterns in Chinese patients with Inflammatory Bowel Diseases: A multicenter cohort study from 1999 to 2020
- P480 Comparison of executive functioning profiles among adults with Crohn's disease and Ulcerative colitis
- P481 profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease
- P482 Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project
- P483 Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar
- P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
- P485 Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease
- P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials
- P487 Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
- P488 Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan®
- P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.
- P490 Patients with inflammatory bowel disease should be vaccinated against pneumococcus and influenza despite immunosuppressive therapy
- P491 Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE
- P492 A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trials
- P493 The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study
- P494 A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
- P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
- P496 Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study
- P497 Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis
- P498 Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess: The Leeds Steroids study
- P499 Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?
- P500 The use of budesonide results in lower risk for infections compared to systemic glucocorticoids
- P501 Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study
- P502 Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China
- P503 Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort study
- P504 Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease
- P505 Smoking is associated with the development of adverse events of biological therapy in patients with Inflammatory Bowel Disease
- P506 Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany
- P507 Need for surgery in patients with ulcerative colitis in the era of biologic therapy.
- P508 The impact of disease duration and early biologic treatment on transmural healing in Crohn’s disease
- P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease
- P510 Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysis
- P511 Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapy
- P512 Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s disease
- P513 Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.
- P514 Optimising response to infliximab in the management of perianal Crohn’s disease
- P515 Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapy
- P516 Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study
- P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
- P518 Partial enteral nutrition use for Crohn’s disease management: a systematic review
- P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
- P520 Very early intestinal ultrasound predicts intravenous corticosteroid failure in hospitalized severe ulcerative colitis patients
- P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenanc
- P522 Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program
- P523 effectiveness of biological treatments for inflammatory bowel disease in the elderly patients
- P524 Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.
- P525 A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD study
- P526 Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients
- P527 Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)
- P528 Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD
- P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).
- P530 Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis
- P531 Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region
- P532 Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels
- P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
- P534 Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
- P535 Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre study
- P536 Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
- P537 Steroid use in patients with immune checkpoint inhibitor colitis
- P538 Implementation of Kono-S anastomosis as a new standard of surgical care
- P539 COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.
- P540 Longitudinal Dynamics of Gut Microbiome and Metabolome After Biological Therapy in Inflammatory Bowel Diseases
- P541 Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease
- P542 Topical tacrolimus versus systemic biological therapy for refractory ulcerative proctitis: a retrospective cohort study
- P543 Point-of-care testing in therapeutic drug monitoring of infliximab
- P544 Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials
- P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
- P546 Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.
- P547 Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
- P548 External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel Disease
- P549 Oxidative stress and antioxidant capacity biomarkers in adults and children with IBD: current update from OxIBDiet trial
- P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU
- P551 Safety and effectiveness of vedolizumab for the treatment of paediatric patients with Inflammatory Bowel Diseases
- P552 Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases
- P554 Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study
- P555 Ustekinumab tissue and serum levels in patients with Crohn’s disease are closely correlated though not consistently associated with objective response after induction.
- P556 The effect of multiple doses of upadacitinib 45 mg on the pharmacokinetics of cytochrome P450 substrates in healthy adult subjects
- P557 Robotic surgery significantly improves outcomes for patients with inflammatory bowel disease
- P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study.
- P559 Cannabis Improves Sleep Quality in Patients with Inflammatory Bowel Diseases in a Prospective Observational Study
- P560 Application of a clinical decision support tool for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicenter study
- P561 Clinical utility of therapeutic drug monitoring of adalimumab using a point of care test
- P562 A Phase 1 Study Evaluating the Effect of Coadministration of Etrasimod on the Pharmacokinetics and Pharmacodynamics of a Monophasic Oral Contraceptive in Healthy Female Volunteers
- P563 Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
- P564 A qualitative exploration of acceptability of long-term use of oral nutritional supplement drinks as partial enteral nutrition in adolescent and adult Crohn's Disease
- P565 COVID-19 vaccination satisfaction and hesitancy in patients with inflammatory bowel disease: “inside referral center” survey
- P566 Humoral immune response to mRNA COVID-19 vaccine in Puerto Ricans with IBD does not differ between class of biologics
- P567 Safety analysis of tofacitinib in ulcerative colitis: Real-world outcomes from a three-year UK observational cohort study
- P568 Impact of Biologics and Small Molecules for Inflammatory Bowel Disease on COVID-19 Related Hospitalization: A Systematic Review and Meta-analysis
- P569 Fecal Microbiome Transplantation for Recurrent C. difficile Colitis: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series
- P570 Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral center
- P571 The Nordic diet as a tool to improve the activity of disease and psycho-emotional wellbeing in patients with mild and moderate Ulcerative Colitis – the pilot study.
- P572 Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it's time to make iron deficiency part of tight monitoring to reach T2T? – preliminary results of a prospective study
- P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications
- P574 Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn‘s disease
- P575 Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results
- P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study
- P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease
- P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability
- P579 Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease
- P580 Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort study
- P581 Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease
- P582 Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
- P583 Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study
- P584 Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease
- P585 Examining faecal incontinence and its impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a multi-country burden of illness study
- P586 Surgical recurrence in Crohn’s Disease: Can we prevent it?
- P587 Disease severity in the INFLAMMATORY BOWEL DISEASES: Do patients and physicians agree?
- P588 T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment
- P589 Total thiopurine exposure and impact on the development of keratinocyte carcinomas in Inflammatory Bowel Disease patients; a case control study
- P590 Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel
- P591 Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis.
- P592 Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients
- P593 Biologicals and small molecule combotherapies: promising experience in refractory IBD patients
- P594 Vedolizumab dose intensification does not always improve treatment persistence.
- P595 Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients
- P596 Adalimumab use in Paediatric Inflammatory Bowel Disease: A single centre real-life experience
- P597 Bone mineral density in patients after total proctocolectomy and pouch surgery due to Ulcerative Colitis have low bone mineral density, and low performance of DXA scans- a cross sectional study
- P598 Indicators for inadequate response among patients with Ulcerative Colitis treated with advanced therapies in German clinical practice
- P599 Azathioprine in the prevention of anti-infliximab antibody formation: A pilot dose-finding study
- P600 Serologic response to COVID-19 vaccines in IBD patients: a prospective study
- P601 Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study
- P602 Tofacitinib treatment prevents post-operative recurrence of Crohn’s Disease modeled by ileocecal resection in HLA-B27 transgenic rats.
- P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas
- P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study.
- P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
- P606 Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease
- P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open
- P608 Systematic review: The impact and importance of body composition in Inflammatory Bowel Disease
- P609 Significant variations in practice in managing mild-Crohn’s disease: results from the 2021 Y-ECCO-ClinCom survey
- P610 Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)
- P611 Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s disease
- P612 Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis
- P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors.
- P614 Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel Disease
- P615 Improving IBD monitoring by understanding preanalytical faecal calprotectin variability
- P616 Safety of COVID-19 vaccines in patients with IBD
- P617 Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with Inflammatory Bowel Disease: our experience in a tertiary hospital.
- P618 Pre-operative oral enteral nutritional optimisation for Crohn’s disease: A retrospective UK tertiary IBD centre cohort study
- P619 Patterns of Anti-TNF Prescribing & Therapy Outcome in a Large Multicentre Cohort of Inflammatory Bowel Disease Patients
- P620 Differences in illness perceptions of Inflammatory Bowel Disease (IBD) between Healthcare Practitioners (HCPs) and patients in a UK tertiary IBD centre.
- P621 Secure Electronic Document Signing Uptake in Biologic Prescribing for Immune Mediate Diseases
- P622 Comparison of long-term outcomes of infliximab and adalimumab in biologic-naïve patients with ulcerative colitis
- P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study
- P624 Long-term effectiveness of anti-TNF therapy in pediatric-onset inflammatory bowel diseases: a population-based study
- P625 Predictors of pancreatitis among patients with inflammatory bowel disease (IBD) treated with vedolizumab (VDZ): Observation from a large global safety database
- P626 Anti-TNF monotherapy is associated with an adverse clinical outcome in female Inflammatory Bowel Disease patients who stop Anti-TNF treatment during the third trimester of pregnancy.
- P627 Variables associated with evolution to moderate to severe Crohn's disease at two reference centers in Salvador, Bahia, Brazil
- P628 Processed and ultra-processed food and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
- P629 Evolution of disease phenotype, time to biological therapy and medium-, long-term surgery rates in Crohn’s disease patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
- P630 Systematic review and meta-analysis: Diagnostic delay and the subsequent impact on the disease course of adult Inflammatory Bowel Disease
- P631 Impact of Covid-19 pandemic on initiation of immunosuppressive treatment in immune-mediated diseases. -A nationwide, retrospective study-
- P632 Estimating indirect and out-of-pocket disease-associated costs in paediatric Inflammatory Bowel Disease: a nation-wide cross-sectional analysis
- P635 Incidence, prevalence, disease phenotype and maximal therapeutic step in Ulcerative Colitis patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem County cohort
- P636 Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study
- P637 Risks of Development of COVID-19 among Patients with Inflammatory Bowel Disease
- P639 Incidence and disease presentation of inflammatory bowel disease in Denmark: initial findings from a Copenhagen IBD Inception Cohort Study
- P640 Incidence, prevalence, disease phenotype and maximal therapeutic step in Crohn’s disease patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
- P641 Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey
- P642 Crossroads of vitamin B6 deficiency and inflammation in inflammatory bowel disease: Preliminary results of a cross-sectional study
- P643 Generalizability of Crohn’s disease randomized controlled trials compared to clinical practice
- P644 Impact of Postoperative Treatment with Immunomodulators and Anti-TNFα agents on long-term Reoperation Rate in ileocaecal Crohn’s Disease.
- P645 Ileocecal resection in paediatric Crohn’s disease based on the Hungarian Paediatric IBD Registry
- P646 Will the screening of SARS-COV-2 infection in IBD infusion centers be useful?
- P647 Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series
- P648 Prevalence and Impact of Alcohol Consumption and Cannabis Use on Inflammatory Bowel Diseases
- P649 The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases – A Danish prospective population-based cohort study
- P650 IBD care from the patient perspective: The patient's turn
- P652 The burden of mental illness, including deliberate self-harm, before and after a diagnosis of IBD, a UK population study.
- P653 The changing epidemiology of IBD in the western world: a population-based study from Denmark
- P654 Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry.
- P655 Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study
- P656 The impact of periodontitis on IBD disease activity
- P657 Persistence in smoking cessation in inflammatory bowel disease (IBD)
- P658 Evolution of disease phenotype, time to biological therapy and medium-, long-term colectomy rates in Ulcerative Colitis patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
- P659 No decrease in number of new Inflammatory Bowel Disease diagnoses in children in the Netherlands during the Covid-19 pandemic: a nationwide retrospective cohort study
- P660 Knowledge, attitudes, and awareness of contraceptive choices in women with Inflammatory Bowel Disease
- P661 Pre-diagnostic vitamin D levels in Inflammatory Bowel Disease
- P662 Colorectal Cancer in Patients with Ulcerative Colitis: A National Cohort Study between 1991-2020
- P663 Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry
- P664 Bidirectional association between inflammatory bowel disease and psoriasis in a pediatric population: A nationwide insurance claim data analysis in South Korea.
- P665 Towards FAIR longitudinal IBD registries: preliminary results of an iterative design process of a reusable and interoperable IBD database model
- P666 Trend of Lower gastrointestinal Endoscopy in Patients with Inflammatory Bowel Diseases : A Nationwide Population-Based Study in South Korea
- P667 Unmet needs in the management of Inflammatory Bowel Diseases in Egypt
- P668 Real world use and adverse events of SARs-CoV-2 vaccination in Greek patients with Inflammatory Bowel Disease
- P669 Validation of prior infliximab exposure and total colectomy outcome in patients with ulcerative colitis in Sweden
- P670 Familial Inflammatory Bowel Disease is associated with a more adverse disease compared to sporadic cases
- P671 Occurrence and clinical impact of eosinophilic esophagitis in a large cohort of children with Inflammatory Bowel Disease.
- P672 Biologic therapy for Inflammatory Bowel Disease in Poland in 2020: nationwide data.
- P673 Trends in inflammatory bowel disease infections and vaccinations in the past four decades - a high-level text mining analysis of PubMed publications.
- P674 Predictors of response to biologics in Crohn's Diseases: A population-based study from the epi-IIRN
- P675 Associations between Inflammatory Bowel Disease, social isolation, and mortality: evidence from UK Biobank cohort study
- P676 Burden of depression and anxiety among inflammatory bowel disease patients in a national cohort in Israel – Data from the EPI-IIRN
- P677 Patients with Inflammatory Bowel Diseases on anti-TNF treatment have impaired antibody production after Anti-SARS-CoV-2 vaccination: Results from a Panhellenic registry
- P678 Rare and severe complications in paediatric Inflammatory Bowel Disease: results of 5 years of international collaboration through the PIBD-SETQuality Safety Registry
- P679 Inflammatory Bowel Disease and cancer risk in the IBSEN study after 30 years of follow-up.
- P680 Epidemiology of Inflammatory Bowel Disease in Poland 2009-2020: nationwide data
- P681 Impact of Crohn’s disease on survival in Korean patients with small bowel adenocarcinoma
- P682 Predictors of response to biologics in Ulcerative Colitis: A population-based study from the epi-IIRN
- P683 Discontinuation of infliximab treatment: a comparison between IBD patients who retransitioned to originator and those who remained on biosimilar
- P684 Increased risk of cardiovascular disease and high risk profiles compatible with metabolic syndrome in patients with Inflammatory Bowel Disease: a cross-sectional analysis of matched cohorts
- P685 Strong Response to SARS-CoV-2 Vaccine Additional Doses among Patients with Inflammatory Bowel Diseases
- P686 Outcomes of COVID-19 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
- P687 Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study
- P688 Sex difference in inflammatory bowel disease patients regarding depression: a nationwide population based study in Korea
- P689 Multicenter, cross-sectional, observational study on Epstein–Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan
- P690 Rates of IBD in New Zealand Māori population at Lakes District Health Board: low but increasing
- P691 Influence of ethnicity on the phenotype and clinical outcomes in Inflammatory Bowel Disease; comparison of a South American with a North American population.
- P692 Clinical, therapeutic and evolutionary profile of fistulizing ano-perineal lesions in Crohn's disease
- P693 Willingness and hesitancy to the telemedicine in patients with inflammatory bowel disease during COVID-19 outbreak. Preliminary results of a survey in an Italian IBD Center
- P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy.
- P695 Attitudes and predictors of COVID-19 vaccine uptake in patients with Inflammatory Bowel Disease
- P696 Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases – secondary analyses from a randomised clinical trial
- P697 Examining the regulatory role of epigenetic and transcriptomic alterations in anti-TNF treatment response and disease progression in patients with Ulcerative Colitis
- P698 Mapping field cancerisation and clonal evolution in IBD colons with dysplasia and colorectal cancer
- P699 Machine Learning-based Prediction for Early Progression in Korean Crohn’s disease: Results from the IMPACT Study
- P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn’s disease in healthy first-degree relatives
- P701 Compositional and functional alterations of the gut microbiome are associated with impaired intestinal permeability in healthy relatives of patients with Crohn's disease
- P702 Faecal Microbiota Transplantation Sculpts the faecal and mucosal microbial and metabolomic profiles in patients with Ulcerative Colitis
- P703 Gut bacteria composition and familiality echo Inflammatory Bowel Disease type and pathological spectrum
- P704 Bifidobacterium longum species protect murine colitis through different activation repertoires of immune cells
- P705 The effects of commonly consumed dietary fibres on the gut microbiome and its fibre fermentative capacity in adults with inflammatory bowel disease in remission
- P706 A distinct subset of tissue-resident Th17 cells expands in the inflamed intestines of Crohn’s Disease patients and responds to colitogenic bacteria
- P707 Microbial signature of the colon is not associated with response to vedolizumab in Crohn’s disease
- P708 Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosa
- P709 Distinct Pattern of Gut Microbial Dysbiosis in Crohn's Disease and Intestinal Tuberculosis - A Machine Learning-based classification model
- P710 Evaluation of helminth extracellular vesicles as a novel therapeutic for inflammatory bowel disease in murine models of colitis
- P711 Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment
- P712 Fungal microbiota composition in Inflammatory Bowel Disease patients in a Norwegian cohort: characterization of disease phenotypes and correlation with clinical activity and disease course.
- P713 Gut microbiota alterations after bowel preparation amongst inflammatory bowel disease patients
- P714 Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study.
- P715 Selective enhancement of immune cell response to opportunistic microorganisms: An innovative proposal for Inflammatory Bowel Disease from an ancient grain.
- P716 Exclusive Enteral Nutrition refurbishes beneficial gut microbiota in patients with Acute Severe Ulcerative Colitis
- P717 Faecal Microbiota Transplant in Ulcerative Colitis (FMTUC) – A randomised clinical trial feasibility study
- P718 Characterization of microbiota and metabolomic profile in human colonic surgical resections of UC patients
- P719 Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection
- P720 Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls
- P721 Faecal microbiota analysis with body composition and nutritional habits simultaneously amongst Crohn’s disease patients
- P722 Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumab
- N01 Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: a multicentre, comparative study.
- N02 The importance of the multidisciplinary team (MDT) and its impact on quality of life and medication adherence in patients with Inflammatory Bowel Disease
- N03 Medication adherence in relation to Health-related Quality of Life in patients with Inflammatory Bowel Disease – a cross-sectional study
- N04 A systematic review of the impact of Inflammatory Bowel Disease (IBD) on family members
- N05 Patient involvement in inflammatory bowel disease therapy and disease-related parameters - is there an association?
- N06 Assessing stakeholder identified barriers and enablers to Ultrasound implementation for assessment of Crohn's Disease in the UK: A qualitative interview study
- N07 Current practices of Ultrasound for assessment of Crohn’s Disease in the UK
- N08 The influence of the Covid-19 epidemic on access to medical advice for children with Inflammatory Bowel Disease (IBD), based on patients from The Children's Memorial Health Institute, Warsaw (IPCZD).
- N09 Disease knowledge and quality of life perception in Inflammatory Bowel Disease: a randomised controlled trial
- N10 The impact of an educational and networking event on nurses caring for Inflammatory Bowel Disease (IBD) paediatric patients receiving biologic therapy
- N11 Development of a young person clinic for 16-24-year-olds with Inflammatory Bowel Disease (IBD), using a multidisciplinary team (MDT) approach.
- N12 Systematic Review: The role of psychological stress in Inflammatory Bowel Disease
- N13 Clinical service delivery implications of the Covid-19 pandemic on people with inflammatory bowel disease: a qualitative study
- N14 Who can do it, if not me? - Identification of biopsychosocial predictors for the quality of life, satisfaction with life, and acceptance of the gastrointestinal disease
- N15 Feedback from adolescents and parents on the transition process to an Irish Adult IBD service
- N16 ‘Same storm, different boat’… Exploring the impact of the COVID-19 pandemic on patients with Inflammatory Bowel Disease, with or without shielding: a qualitative study
- N17 Co Design of young person’s IBD clinic for 16-24 year olds
- N18 Introduction of inflammatory bowel disease specialized dietitian and nutritional status in a multidisciplinary IBD team
- N19 Improving the standard of care for patients with IBD - translating the N-ECCO Consensus Statements
- N20 Safety of extended blood monitoring for adult Inflammatory Bowel Disease (IBD) patients on oral azathioprine during the COVID-19 pandemic: a single-centre audit